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Abstract
Background: Glycogen synthase kinase 3 (GSK3) is a central regulator of cellular
metabolism, development and growth. GSK3 activity was thought to oppose
tumourigenesis, yet recent studies indicate that it may support tumour growth in
some cancer types including in non-small cell lung carcinoma (NSCLC). We
examined the undefined role of GSK3 protein kinase activity in tissue from human
NSCLC.
Methods: The expression and protein kinase activity of GSK3 was determined in
29 fresh frozen samples of human NSCLC and patient-matched normal lung tissue
by quantitative immunoassay and western blotting for the phosphorylation of three
distinct GSK3 substrates in situ (glycogen synthase, RelA and CRMP-2). The
proliferation and sensitivity to the small-molecule GSK3 inhibitor; CHIR99021, of
NSCLC cell lines (Hcc193, H1975, PC9 and A549) and non-neoplastic type II
pneumocytes was further assessed in adherent culture.
Results: Expression and protein kinase activity of GSK3 was elevated in 41% of
human NSCLC samples when compared to patient-matched control tissue.
Phosphorylation of GSK3a/b at the inhibitory S21/9 residue was a poor biomarker
for activity in tumour samples. The GSK3 inhibitor, CHIR99021 dose-dependently
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reduced the proliferation of three NSCLC cell lines yet was ineffective against type
II pneumocytes.
Conclusion: NSCLC tumours with elevated GSK3 protein kinase activity may have
evolved dependence on the kinase for sustained growth. Our results provide further
important rationale for exploring the use of GSK3 inhibitors in treating NSCLC.
Introduction
Lung cancer is the leading cause of cancer death worldwide and non-small cell
lung carcinoma (NSCLC) accounts for 85–90% of all cases. The five year survival
rate in Europe is 8% [1] and the median survival after diagnosis is 4–5 months if
left untreated [2]. Advances in the management of NSCLC using surgery,
radiotherapy and chemotherapy have only modestly improved patient survival.
The more recent development of the epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitors, gefitinib and erlotinib, have provided substantial
benefit in a subgroup of patients carrying activating mutations in the EGFR gene
[3]. However, this subgroup represents only 10% of all cases of NSCLC in the
western world [4] and so there is a continuing need to explore the molecular basis
of NSCLC and identify new drug targets for prevention and therapy.
Glycogen synthase kinase 3 (GSK3) was first identified in 1980 as an enzyme
that phosphorylated and inactivated glycogen synthase (GS) [5]. There are two
isoforms of GSK3, which are semi-redundant and ubiquitously expressed in
tissues. The a-isoform encodes a 51 kDa polypeptide and the b-isoform a 47 kDa
polypeptide [6, 7]. GSK3 is an unusual kinase in that it is generally active in
resting cells and can be inactivated by serine phosphorylation on S21 in GSK3a
and S9 in GSK3b [8]. The predominant kinase responsible for this phosphor-
ylation event is Akt, although these sites can also be phosphorylated by PKA,
p90Rsk and S6K1 [9]. Growth factors promote glycogen and protein synthesis via
phosphorylation and inhibition of GSK3 and the consequent activation of GS and
translational initiation factor eIF2B respectively [10]. GSK3 is also phosphorylated
on tyrosine residues (GSK3a Y279 and GSK3b Y216) and this activates the kinase
[11].
The PI3K/Akt and the Wnt pathways are frequently activated in cancer and
both result in inactivation of GSK3 [12]. Consequently the activity of GSK3 has
classically been thought to suppress oncogenesis. Indeed, the kinase has been
reported to be frequently inactivated in human tumours [13] including oral [14],
liver [15] and lung [16]. In contrast, several studies now support the notion that
in certain tumour types GSK3 functions to promote tumourigenesis. For example,
pharmacological inhibitors of GSK3 block proliferation of various cancer cell
lines, such as pancreatic [17], ovarian, [18, 19] mixed lineage leukemia [20] and
glioma [21]. Additionally, increased expression and/or activity of GSK3 has been
observed in various human cancers including colorectal cancer [22], osteosarcoma
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[23], renal cell carcinoma [24] and lung [25]. These studies suggest that GSK3 can
exhibit both pro-tumour and anti-tumour activity and that this may depend on
the tumour type. In none of these studies, however, was GSK3 protein kinase
activity systematically examined, which is an important omission given its
complex regulation by multisite phosphorylation.
In this study, we explored the role of GSK3 in NSCLC by examining its
expression and protein kinase activity in freshly isolated NSCLC tissue compared
to patient-matched control tissue, and the sensitivity of NSCLC cell lines to
inhibition of GSK3 using a small molecule inhibitor. We show that GSK3
expression and protein kinase activity is elevated in 41% of NSCLC tumours and
that GSK3 protein kinase activity supports the proliferation of NSCLC cell lines,
but not of immortalised pneumocytes. These data suggest the potential for a
subset of patients with NSCLC to benefit from the therapeutic use of GSK3
inhibitors previously developed for other human diseases.
Materials and Methods
Patients and tissue samples
Ethics statement: Patients with suspected lung cancer were identified from an
elective thoracic surgery list at the Bristol Royal Infirmary, Bristol, UK. The study
was approved by the local research ethics committee: UK National South West 4
Research Ethics Committee (REC) Southmead Hospital, Bristol BS10 5NB. REC
no: 07/Q2002/6, South West 4 REC. Written consent was obtained from all
patients. Collection of samples and details of the cohort are the same as previously
described [26]. In brief, three distinct samples of the tumour and adjacent normal
tissue from the resection margin were taken and flash frozen in liquid nitrogen as
quickly as possible (average time taken to freeze samples after surgical removal
was 15.9 minutes; range 8–25 minutes). A pathologist recorded the histology and
stage of the tumour, and made an assessment of the percentage of each sample
that was tumour. Only those NSCLC tumour samples comprising at least 90%
tumour tissue were included in the study. All samples were stored at 280 C˚ until
required for analysis.
Materials
The GSK3 inhibitor CHIR99021 (Stemgent, Cambridge, MA, USA#04-0004) was
dissolved in DMSO and diluted in culture medium before use. Rabbit polyclonal
pCRMP (Thr514) and pGS (S641) antibodies were from Cell Signaling
Technology (Boston, MA). Murine anti-F1-ATPase and rabbit polyclonal pNFkB
p65 (Ser468) antibodies were from Santa Cruz Biotechnology Inc. (Santa Cruz,
CA), murine anti-GSK3a/b antibody was purchased from Millipore (Millipore,
Hertfordshire, UK), and donkey horse-radish peroxidase-conjugated anti-mouse
IgG and anti-rabbit IgG antibodies were from Jackson ImmunoResearch
Laboratories (Bar Harbor, ME). Luminex Multiplex Bead Immunoassay kits
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(Invitrogen Ltd., Paisley, UK; buffer kit #LHBO002) were used to analyse pGS
(S641/645) (LHO0731) and GSK3b (LHO0451) in patient samples and Luminex
Bio-Plex Phosphoprotein assay kits (Bio-rad, Hemel Hempsted, UK; buffer kit #
171-304004) were used to analyse pGSK3 (S21/9) (#171V23318).
Cell culture
Hcc193, H1975, PC9 and A549 cells were from the National Institutes of Health
NCI-60 panel. Cell lines are regularly tested (every 6 months) using short tandem
repeat (STR) profiling by the cell authentication service offered by LGC
(Teddington, UK). Type II pneumocytes were generated from primary cultures
and isolated as described [27]. The cell lines were cultured in ‘‘growth medium’’
consisting of RPMI 1640 or DCCM-1 (type II pneumocytes) supplemented with
10% foetal bovine serum (FBS, Invitrogen, Paisley, UK), 20000 U/ml penicillin,
7 mM streptomycin and 200 mM glutamine. All cell lines were grown at 37 C˚ in a
humidified atmosphere supplemented with 5% (v/v) CO2.
For western blotting experiments cells were seeded in 6 or 12 well experimental
plates so that the cultures were 90% confluent after 24 h. Cells were then cultured
in the presence or absence of CHIR99021 for 24 h. The final DMSO concentration
in all cultures was 0.5% (v/v). Cells were then transferred to ice and protein was
extracted as previously described [28].
Growth assays
For analysis of adherent cell growth, cell lines were trypsinised and gently passed
through an 18G needle to form individual single cell suspensions. Cells were
seeded (16103 cells/well) in 96 well plates in RPMI 1640 containing 10% (v/v)
FBS, 100 U/ml penicillin, 0.1 mg/ml streptomycin and 2 mM L-glutamine. After
24 h medium was replaced with medium containing CHIR99021 (1, 5 or 10 mM)
or DMSO, with cells treated in triplicate. Cells were incubated for 120 h, at which
point 10% by volume of Alamar Blue (Serotec, Kidlington, UK) was added to the
wells and the cultures incubated for a further 2–5 hours. Metabolically active cells
convert Alamar Blue to a fluorescent indicator so that quantification of
fluorescence is a measure of the number of living cells. Fluorescence was analysed
using a Perkin Elmer Fusion plate reader with 535 nm excitation and 590 nm
emission filters.
Preparation of tissue lysates
Frozen tissue samples were homogenised and extracted as previously described
[26]. In brief, a Polytron homogeniser was used to generate tissue lysates in 1%
NP40 lysis buffer. Tissue lysates were rotated end-over-end at 4 C˚ for 30 min, and
rested on ice for 15 min before centrifugation at 16,0006g for 15 min to remove
insoluble material. Protein concentration was determined by BCA assay (Thermo
Scientific, IL, USA) and tissue lysates were stored at 280 C˚.
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Luminex (xMAP) assays
Multiplex Bead Immunoassays (Invitrogen) and Bio-Plex Phosphoprotein assays
(Bio-Rad) were carried out in individual plates with their own buffers and
standards following the directions of the manufacturer. Lung tissue lysates were
diluted in extraction buffer to 1 mg/ml (Invitrogen) or 0.4 mg/ml (Biorad)
followed by dilution to 0.2 mg/ml in assay diluent. Aliquots of 50 ml containing
10 mg of protein were combined with coated beads. Incubations and washes were
performed using a vacuum manifold in the 96-well filter membrane plates
supplied. Plates were analysed with a Luminex 200
TM
instrument. An acquisition
gate was set between 8000 and 13500 for the doublet discriminator for a sample
volume of 50 ml, with 50 events/region being acquired. Three separate samples of
tumour tissue and three separate samples of normal tissue from each individual
patient were analysed in duplicate in each Luminex assay. The median
fluorescence intensity was determined. Data are expressed as mean ¡ SEM, and
the strength of evidence for the difference in phosphorylation/expression between
the normal and tumour samples was determined by a Kruskal-Wallis rank order
test (p,0.05).
Western blotting analysis
NSCLC cell or tissue lysates (15 mg protein) were subjected to SDS-PAGE and
western blotting as previously described [26]. Lysates were separated using 4–12%
Bis-Tris gradient gels (Invitrogen Ltd., Paisley, UK), proteins were transferred to
polyvinylidene difluoride membranes (Millipore, Hertfordshire, UK) and blocked
using 5% (w/v) bovine serum albumin for 1 hour. Membranes were washed,
incubated with primary antibody (1 mg/ml) overnight before washing and
incubating with the appropriate secondary antibodies for 1 hour. Immunoblots
were visualised using an Enhanced ChemiLuminescence detection system (ECL;
Amersham Biosciences).
Results
Analysis of GSK3 expression in human NSCLC
The cohort used in this study comprised 29 patients undergoing thoracic surgery
for suspected lung cancer. Following resection from the patient three samples of
tumour were snap frozen in liquid nitrogen. Only tumour samples confirmed by
analysis of frozen sections to consist of at least 90% tumour tissue were then
retained for use in the study. Three samples of normal lung tissue were also taken
from the resection margin surrounding the tumour and snap frozen. The use of
patient-matched normal tissue allowed us to determine whether protein
expression and phosphorylation was increased, decreased or unchanged in the
tumour relative to normal lung from that particular individual.
For all 29 patients, each of the three separate samples of tumour and three
samples of patient-matched normal tissue were analysed using Luminex (xMAP)
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technology to assess the level of GSK3 expression and activity in NSCLC tissue in
comparison to the normal lung samples. Luminex (xMAP) technology was
chosen, as it is a directly quantitative technique in comparison to semi-
quantitative western blotting (S1 Figure). Fig. 1A shows data for the expression
level of GSK3b in the tumour samples (dark grey bars) compared to samples of
patient-matched normal tissue (light grey bars). These data are reorganised in
Fig. 1B according to the magnitude of the fold-change; from highest fold-increase
to highest fold-decrease in tumour compared to normal tissue.
GSK3b protein expression was increased in 14/29 (48%) of tumours (at
p,0.05; Kruskal-Wallis test) when compared to the patient-matched normal
tissue, decreased in 3/29 (10%) tumours (p,0.05) and unchanged in the
remaining 12 tumours (i.e. p.0.05). Samples from nine patients were further
analysed by western blotting with an anti-GSK3 antibody that recognises both the
a and b isoforms. Three patients in which GSK3b was increased (Fig. 2A), three
where it was decreased (Fig. 2B) and three where it was unchanged (Fig. 2C) were
analysed. F1-ATPase expression demonstrated equal protein loading. The results
support the Luminex data for GSK3b (Fig. 1) and reveal that changes in GSK3b
expression were mirrored by equivalent changes in the level of GSK3a.
Analysis of GSK3 protein kinase activity in human NSCLC
We next assessed whether increased GSK3 expression resulted in increased activity
of the protein in NSCLC by analysing GSK3 phosphorylation and downstream
signalling. GSK3a/b phosphorylation on S21/9 was analysed in all patients using
Luminex technology (S2 Figure). S21/9 phosphorylation, which inhibits the
enzyme, was increased in 25/29 (86%) of tumours (at p,0.05; Kruskal-Wallis
test) when compared to matched normal tissue and in the remaining 4 tumours
was unchanged (i.e. p.0.05). All tumours that exhibited an increase in GSK3
expression by Luminex analysis (Fig. 1) also showed a parallel increase in GSK3
S21/9 phosphorylation. After normalisation of GSK3 S21/9 phosphorylation to
the level of GSK3 expression, the net level of serine phosphorylation in all but one
of these tumours is no longer increased (S3 Figure). This strongly suggests that the
gross increase in S21/9 phosphorylation observed in these tumours is
predominantly a reflection of the elevation of GSK3 expression and does not
necessarily indicate a decreased activity of the enzyme.
To obtain a direct readout of in vivo GSK3a/b activity, rather than inferring
activity by measuring levels of S21/9, GSK3 activity was determined by measuring
the phosphorylation of three distinct and well established downstream GSK3
substrates. The phosphorylation of glycogen synthase (GS) by GSK3 on S641/645
[29] was measured by Luminex detection. Fig. 3A and 3B show that GS S641/645
phosphorylation was increased in 14/29 tumours (48%; p,0.05) when compared
to patient-matched normal tissue, decreased in 6/29 (21%; p,0.05) and
unchanged (i.e. p.0.05) in the remaining nine tumours.
The data were there then coded for the levels of expression and S21/9
phosphorylation of GSK3, and for GS S641/645 phosphorylation according to
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whether they increased or decreased at p,0.05. The coded data are represented
within the chart shown in Fig. 4 and are grouped according to the direction of
change in GSK3b expression and GS phosphorylation. 12/29 (41%) of tumours
had a parallel increase in GSK3b expression and GS phosphorylation on S641/645
relative to normal tissue (these tumours are termed ‘Group 1’ in Fig. 4). These
data suggest that GSK3 protein activity is elevated in these tumours, despite
the gross in S21/9 phosphorylation. Indeed, upon normalisation of GSK3
Figure 1. Expression of GSK3 in NSCLC tumour tissue in comparison to patient-matched normal lung tissue. Three distinct samples from patient-
matched normal (N1-3) and tumour (T1-3) tissues were analysed using Luminex (xMAP) technology to determine the level of GSK3b expression. A:
Quantified data for all 29 patients. Each bar represents the average expression for normal (N1-3; light grey) or tumour (T1-3; black) tissue for each patient
(mean¡ SEM). The strength of evidence for a difference in expression between the normal and tumour samples was determined by a Kruskal-Wallis test,
and * indicates p,0.05. B: The percentage change in GSK3 expression in tumour samples in comparison to patient-matched normal tissue where patients
are ranked in order of the extent of the percentage change in expression.
doi:10.1371/journal.pone.0114725.g001
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phosphorylation to total GSK3 the net level of serine phosphorylation is no longer
increased in all but one Group 1 tumour.
To further investigate the changes in GSK3 protein kinase activity, western
blotting was used to analyse a subset of Group 1 tumours (03, 13, 17, 23 and 27)
(Fig. 5A) for the phosphorylation of GS and two additional established GSK3
substrates: the p65-RelA subunit of NFkB on S468 [30] and CRMP on T514 [31].
Phosphorylation of all three GSK3 substrates was increased in Group 1 tumour
tissue in comparison to normal, and this was particularly marked in the case of
CRMP T514 phosphorylation (Fig. 5A). To demonstrate that substrate
phosphorylation correlates with GSK3 expression levels we have also included two
non-Group 1 tissue samples (patients 22 and 15 have decreased and unchanged
expression of GSK3 in their tumour tissue respectively). That these proteins are
GSK3 substrates in NSCLC cells was confirmed in the A549 line in which GSK3a/
b inhibitor CHIR99021 decreased the phosphorylation of all three substrates
(Fig. 5B).
GSK3 protein activity is required for growth of NSCLC cell lines
As an increase in GSK3 activity in 41% of the NSCLC patient tumours was
observed, we explored whether GSK3 protein activity may contribute to tumour
cell proliferation in a subset of NSCLC cell lines. We employed a cell-permeant
ATP-competitive inhibitor of GSK3; CHIR99021, four NSCLC cell lines (Hcc193,
H1975, PC9 and A549) and immortalised normal human lung alveolar cells (type
Figure 2. GSK3a/b expression in selected patients. Three distinct samples from normal (N1-3) and patient-
matched tumour (T1-3) tissues were separated on SDS-PAGE gels. Expression of GSK3a/b was determined
by western blotting. An anti-F1-ATPase antibody was used as a control for protein loading.
doi:10.1371/journal.pone.0114725.g002
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II pneumocytes). CHIR99021 is the most selective GSK3 inhibitor currently
available and inhibits both GSK3 isoforms with 350-fold greater potency than it
does other cyclin-dependent kinases (CDKs) [32, 33].
Cells were cultured in the presence or absence of the GSK3 inhibitor for 120 h.
CHIR99021 decreased the proliferation of three NSCLC cell lines in a dose
dependent manner. The proliferation of type II pneumocytes was not inhibited
(Fig. 6A). In contrast to the other NSCLC cell lines, A549 cell proliferation was
not affected by the inhibitor (S4 Figure).
Figure 3. Phosphorylation of GS on S641/645 in NSCLC tumour tissue in comparison to patient-matched normal lung tissue. Samples were anal-
Fig. 1. A: The extent of GS phosphorylation in normal (N1-3; light grey) or tumour (T1-3;
¡ SEM; * indicates p,0.05). B: Shows the percentage change in GS (S641/645) phosphorylation in tumour
doi:10.1371/journal.pone.0114725.g003
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black) tissue for each patient (mean
samples in comparison to patient-matched normal tissue with patients ranked according to the percentage change in phosphorylation.
ysed using Luminex (xMAP) technology exactly as described in
To relate the effect of CHIR99021 on cell proliferation to the inhibition of the
kinase itself, the phosphorylation of GSK3 substrates CRMP, NFkB and GS was
assessed following cell treatment with the GSK3 inhibitor. In all cell lines
(including type II pneumocytes) the phosphorylation of CRMP on T514 and GS
on S641 was reduced in a dose-dependent manner by CHIR99021 (Fig. 6B). By
contrast the phosphorylation of NFkB on S468 was largely unaffected by the
inhibitor in the NSCLC cell lines but was reduced in type II pneumocytes (Fig. 6B)
and in A549 cells (S4 Figure).
Discussion
This study provides the first evidence that GSK3 protein kinase activity is elevated
in early stage NSCLC and that this may contribute to the cancer cell phenotype.
The expression and protein kinase activity of GSK3 was elevated in 41% of
NSCLC tumours in comparison to patient-matched normal tissue derived from
the surgical resection margin. In addition, GSK3 was found to positively regulate
Figure 4. Summary of GSK3 activity in all patients. Three distinct samples from normal and patient-matc-
b expre-
a/b phosphorylation (S21/9). GSK3 phosphorylation has also
between the normal and tumour samples was determined by Kruskal-Wallis test. Expression/phosphorylation
of each protein/site was then coded according to whether it increased (black), decreased (grey) at p#0.05 or
remained unchanged (white; p.0.05) in the tumour samples relative to normal tissue. The coded data were
then grouped according to the direction of change in GSK3 expression: patients in Group I showed an
increase in GSK3 expression and GS phosphorylation.
doi:10.1371/journal.pone.0114725.g004
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been normalised to GSK3 expression. The strength of evidence of difference in expression/phosphorylation
hed tumour tissues were analysed using Luminex (xMAP) technology to determine the level of GSK3
ssion, GS phosphorylation (S641/645) and GSK3
Figure 5. Phosphorylation of downstream GSK3 substrates in selected patients. A: Three distinct
Expression of GSK3 and phosphorylation of GS (S641), NFkB p65 (S468) and CRMP (T514) was determined
by western blotting with specific antibodies as indicated. An anti-F1-ATPase antibody was used as a control
for protein loading. B: A549 cells were cultured in the absence and presence of 10 mM CHIR99021. Protein
was extracted and lysates were separated on SDS-PAGE gels. Expression of GSK3 and phosphorylation of
GS (S641), NFkB p65 (S468) and CRMP (T514) was determined by western blotting.
doi:10.1371/journal.pone.0114725.g005
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samples from normal (N1-3) and patient-matched tumour (T1-3) tissues were separated on SDS-PAGE gels.
cell proliferation in three NSCLC cell lines, but not in non-neoplastic type II
pneumocytes.
The expression level of GSK3 has been studied in various cancers. For example
a reduction has been reported in human squamous and basal cell skin carcinoma
[34], whilst in human colorectal and gastric cancer tissue an increase in expression
relative to non-neoplastic tissue has been reported [22, 35]. In addition to analysis
of GSK3 expression, kinase activity in cancer has been reported on the basis of the
phosphorylation status of the kinase. In oral, laryngeal, esophageal and salivary
gland cancer [14], breast cancer [36] phosphorylation on the inhibitory serine
Figure 6. Inhibition of GSK3 suppressors cell proliferation in NSCLC cells. A: NSCLC cells (PC9, H1295
and Hcc193) and type II pneumocytes were cultured for 120 h in the presence or absence of GSK3 inhibitor,
CHIR99021 (0, 1, 5 and 10 mM). After 120 h the extent of cell metabolism was assessed using alamar blue.
Fluorescence was analysed using a Fusion plate reader and 535 nm excitation and 590 nm emission filters.
Each data point represents the average fluorescence over three replicate experiments (mean ¡ SEM;
* indicates p,0.05, ** p,0.001 relative to the growth of type II pneumocytes). B: NSCLC cells (PC9, H1975
and Hcc193) and type II pneumocytes were cultured in the absence and presence of CHIR99021 (0.05, 0.25,
1, 5 and 10 mM). Protein was extracted and lysates were separated on SDS-PAGE gels. Phosphorylation of
GS (S641), NFkB p65 (S468) and CRMP (T514) was determined by western blotting. An anti-a-tubulin
antibody was used as a control for protein loading.
doi:10.1371/journal.pone.0114725.g006
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(GSK3b S9) was reported to be elevated and the activity of GSK3 was reasoned to
be reduced as a result.
In NSCLC GSK3b has been recently reported to be over-expressed in tumour
tissue compared to normal tissue isolated from the resection margin and this was
found to correlate with poor patient prognosis [25]. In a separate study
phosphorylation of GSK3a/b on the inhibitory site, S21/9, was also found to be
increased in NSCLC tumour tissue compared to normal, and this too correlated
with poor patient prognosis [16]. However, in neither study protein kinase
activity is measured.
We therefore sought to clarify this discrepancy and our study is the first to
determine GSK3 protein kinase activity in situ in NSCLC. The increase in GSK3b
expression we observed in Group 1 tumours (Fig. 1) was frequently accompanied
by an equivalent increased phosphorylation of the inhibitory S21/9 sites (Fig. 4
and S1 Figure). This is consistent with the observations of [25] and [16],
respectively. In addition to this we demonstrated that GSK3b over-expression was
often accompanied by GSK3a overexpression (Fig. 2). However, when the level of
GSK3 phosphorylation was normalized to the level of GSK3 expression (S3
Figure), Group 1 tumours no longer displayed significantly elevated GSK3 serine
phosphorylation (Fig. 5). Furthermore, and most importantly, when we measured
GSK3 protein activity in situ through examination of the phosphorylation of three
distinct proteins on well established GSK3 phosphorylation sites (glycogen
synthase (S641/645), CRMP (T514) and NFkB p65-RelA (S468); Figs 3–5), it was
increased in the tumours compared to patient matched control tissue. Our data
therefore show that activity of the kinase cannot be inferred from serine
phosphorylation state alone and that phosphorylation of GSK3 substrates should
be measured to properly assess GSK3 activity. Consistent with this, the degree of
GSK3a/b inactivation by serine phosphorylation on S21/9 is only approximately
50% [37]. Furthermore, Lim et al have shown that the phosphorylation status of
GSK3 substrates (including CRMP) is inconsistent with the level of phosphor-
ylation of GSK3b at serine 9 [38]. Our data showing elevated GSK3 protein kinase
activity in NSCLC is, therefore, an important advance in understanding the role of
GSK3 in NSCLC.
It is of interest to note that NFkB, one of the GSK3 substrates used here as an
indicator of GSK3 activity, is a transcription factor involved in the regulation of
cell proliferation, differentiation and apoptosis, is deregulated in many tumours
[39] and can be activated through phosphorylation of the p65-RelA subunit by
GSK3 [40]. GSK3 inhibition has been shown to be accompanied by a reduction in
NFkB activity in osteosarcoma [23], renal cell carcinoma [24], glioma [21],
pancreatic [17, 41, 42] and chronic lymphocytic leukaemia [35] cell lines.
However, in our study we found that phosphorylation of NFkB was insensitive to
GSK3 inhibition in NSCLC cell lines sensitive to CHIR99021, suggesting GSK3
activity on NFkB is unlikely to be involved in the affect of the kinase on NSCLC
cell proliferation/viability. In contrast, phosphorylation of GS and CRMP-2 was
decreased upon GSK3 inhibition; this suggests they could be involved in
mediating the proliferation/viability of NSCLC.
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Having demonstrated an increase in GSK3 activity in human tumour tissue we
used NSCLC cell lines to investigate whether GSK3 activity was able to support
cellular proliferation. The proliferation of three NSCLC cell lines (Hcc193, H1975
and PC9) was sensitive to GSK3 inhibition in a dose dependent manner using a
specific inhibitor of GSK3 (Fig. 6). The proliferation of type II pneumocytes was
insensitive to GSK3 inhibition, despite exhibiting inhibitor-sensitive GSK3 activity
similar to that found in Hcc193, H1975 and PC9 cells (Fig. 6). This suggests that
these NSCLC cells have become dependent on the GSK3 pathway for proliferation
during tumourigenesis. Consistent with the role of GSK3 in supporting a tumour
phenotype, its inhibition has been shown to promote apoptosis in NSCLC cell
lines [43, 44]. By contrast we found that proliferation of another NSCLC cell line,
A549 was insensitive to GSK3 inhibition. This is inconsistent with the observation
that siRNA-mediated knockdown of GSK3 A549, led to reduced cell proliferation
[25], however others have not observed a growth inhibitory affect of CHIR99021
on this cell line [44]. That not all NSCLC cell lines are sensitive to GSK3
inhibition is unsurprising given our human tissue data, as not all patients have
upregulated GSK3 activity in their tumour tissue.
The difference we have noted in sensitivity of type II pneumocytes and NSCLC
cell lines to GSK3 inhibition allows for the possibility for a therapeutic window in
which the proliferation of tumourigenic cells can be inhibited but that of non-
neoplastic cells is relatively unaffected. Consistent with this, the growth of
HEK293 [22, 35], cultured human mammary epithelial cells (HMEC) and
embryonic lung fibroblasts [17] are also insensitive to pharmacological inhibition
of GSK3. Furthermore, Shakoori et al have reported that a GSK3 inhibitor was
able to block the growth of human colon cancer xenografts in mice without
adverse side effects [45].
Despite this, treating patients with inhibitors of a kinase known to act as a
tumour suppressor in some pathways (such as the Wnt pathway) represents a
potential concern [11]. This is, however, mitigated by the finding that more than a
75% inhibition of GSK3 is required to affect b-catenin phosphorylation and
stability [7]. Additionally, a lack of correlation between GSK3 activity and nuclear
b-catenin expression has been shown in colorectal [22], pancreatic [46] and
gastric cancer [47], and this may also be true in NSCLC [25]. This suggests that
GSK3 has a signalling role independent of Wnt in several tumour types.
Furthermore, psychiatric patients receiving long-term lithium carbonate (an
inhibitor of GSK3) have a significantly reduced risk of cancer than the general
population [48]. Taken together these data suggest that GSK3 inhibitors may have
the potential to act as effective targeted therapeutics in cancer while
demonstrating an acceptable therapeutic window.
To conclude, we provide the first demonstration of elevated GSK3 protein
kinase activity in a large subset of human early stage NSCLC and show that
NSCLC cell lines depend on GSK3 activity for proliferation. Thus, levels of GSK3
expression and protein kinase activity may facilitate prediction of an anti-tumour
response to pharmacological inhibition of GSK3 in individual patients.
Importantly GSK3 activity was assessed in NSCLC tissue using known substrates
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of the kinase; we found activity could not be assumed on the basis of serine
phosphorylation alone. This finding has very important implications for the
interpretation of previous studies and of those going forward. Our findings
further indicate the potential of treating NSCLC patients with currently available
GSK3 inhibitors.
Supporting Information
S1 Figure. Validation of the Luminex X-MAP Technology assay. A: Lysate from
human lung tumour tissue from one patient was analysed using Luminex (xMAP)
technology to determine the level of GSK3b expression. The experiment was
performed in tripliacte and each bar represents the average expression (mean ¡
SEM). Lysate containing increasing amounts of protein were analysed. The result
was validated by western blotting. B: A549 cells were cultured in the absence and
presence EGF (25 ng/ml) alone and EGF with AKTi (10 mM). Protein was
extracted and lysates were either analysed using Luminex (xMAP) technology or
separated on SDS-PAGE gels to determine the level of GSK3a/b phosphorylation.
doi:10.1371/journal.pone.0114725.s001 (TIFF)
S2 Figure. Phosphorylation of GSK3a/b on S21/9 in NSCLC tumour tissue in
comparison to patient-matched normal lung tissue. Three samples from
patient-matched normal (N1-3) and tumour (T1-3) tissues were analysed using
Luminex (xMAP) technology to determine the level of GSK3a/b phosphorylation.
A: Quantified data for all 29 patients. Each bar represents the average
phosphorylation for normal (N1-3; light grey) or tumour (T1-3; black) tissue for
each patient (mean ¡ SEM). The strength of evidence for a difference in
phosphorylation between the normal and tumour samples was determined by a
Kruskal-Wallis test, and * indicates p,0.05. B: The percentage change in GSK3
phosphorylation in tumour samples in comparison to patient-matched normal
tissue where patients are ranked in order of the extent of the percentage change in
expression.
doi:10.1371/journal.pone.0114725.s002 (TIFF)
S3 Figure. Normalisation of GSK3a/b phosphorylation on S21/9 to total GSK3
in NSCLC tumour tissue in comparison to patient-matched normal lung tissue.
GSK3a/b phosphorylation (S2 Figure) was normalised to levels of total GSK3
(Fig. 1). A: Quantified data for all 29 patients. Each bar represents the average
normalised phosphorylation for normal (N1-3; light grey) or tumour (T1-3;
black) tissue for each patient (mean ¡ SEM). The strength of evidence for a
difference in phosphorylation between the normal and tumour samples was
determined by a Kruskal-Wallis test, and * indicates p,0.05. B: The percentage
change in normalised GSK3 phosphorylation in tumour samples in comparison to
patient-matched normal tissue where patients are ranked in order of the extent of
the percentage change in expression.
doi:10.1371/journal.pone.0114725.s003 (TIFF)
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S4 Figure. Inhibition of GSK3 does not suppress cell growth in A549 cells. A:
A549 NSCLC cells were grown for 120 h in the presence or absence of GSK3
inhibitor, CHIR99021 (0, 1, 5 and 10 mM). After 120 h the extent of cell
metabolism was assessed using alamar blue. Fluorescence was analysed using a
Fusion plate reader and 535 nm excitation and 590 nm emission filters. Each data
point represents the average fluorescence over three replicate experiments. B:
A549 cells were cultured in the absence and presence of CHIR99021 (0.05, 0.25, 1,
5 and 10 mM). Protein was extracted and lysates were separated on SDS-PAGE
gels. Phosphorylation of GS (S641), NFkB p65 (S468) and CRMP (T514) was
determined by western blotting. An anti-a-tubulin antibody was used as a control
for protein loading.
doi:10.1371/journal.pone.0114725.s004 (TIFF)
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